Jill L Schwartz
Overview
Explore the profile of Jill L Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thurman A, Brache V, Cochon L, Ouattara L, Chandra N, Jacot T, et al.
PLoS One
. 2022 Oct;
17(10):e0275794.
PMID: 36215267
Multipurpose prevention technologies (MPTs), which prevent sexually transmitted infection(s) and unintended pregnancy, are highly desirable to women. In this randomized, placebo-controlled, phase I study, women used a placebo or tenofovir...
2.
McGowan I, Kunjara Na Ayudhya R, Brand R, Marzinke M, Hendrix C, Johnson S, et al.
AIDS Res Hum Retroviruses
. 2021 Sep;
38(4):279-287.
PMID: 34541872
The Microbicide Trials Network-017 study was undertaken to characterize the safety, acceptability, pharmacokinetic (PK), and pharmacodynamic profile of the reduced-glycerin (RG) 1% tenofovir (RG-TFV) gel compared to oral emtricitabine/tenofovir disoproxil...
3.
Thurman A, Schwartz J, Cottrell M, Brache V, Chen B, Cochon L, et al.
EClinicalMedicine
. 2021 May;
36:100893.
PMID: 34041459
Background: Daily oral emtricitabine (FTC, F)/tenofovir disoproxil fumarate (TDF) combination is approved for HIV pre-exposure prophylaxis (PrEP) in men and women. Tenofovir alafenamide fumarate (TAF) is a newer, more potent...
4.
Browne E, Montgomery E, Mansfield C, Boeri M, Mange B, Beksinska M, et al.
AIDS Behav
. 2019 Nov;
24(5):1443-1451.
PMID: 31696371
As new female-initiated HIV prevention products enter development, it is crucial to incorporate women's preferences to ensure products will be desired, accepted, and used. A discrete-choice experiment was designed to...
5.
Mansoor L, Yende-Zuma N, Baxter C, Mngadi K, Dawood H, Gengiah T, et al.
J Int AIDS Soc
. 2019 Sep;
22(9):e25381.
PMID: 31507088
Introduction: Tenofovir-containing oral pre-exposure prophylaxis (PrEP) is recommended for those at substantial risk as part of combination HIV prevention. However, there are limited data, beyond clinical trial settings, to guide...
6.
Walsh T, Snead M, St Claire B, Schwartz J, Mauck C, Frezieres R, et al.
Contraception
. 2019 Aug;
100(5):406-412.
PMID: 31381878
Objective: To investigate whether rates of self-reported Woman's Condom (WC) clinical failure and semen exposure from a functionality study are comparable to results from a contraceptive efficacy substudy. Study Design:...
7.
Thurman A, Schwartz J, Ravel J, Gajer P, Marzinke M, Yousefieh N, et al.
PLoS One
. 2019 May;
14(5):e0217229.
PMID: 31107913
Recent data support that the vaginal microbiota may alter mucosal pharmacokinetics (PK) of topically delivered microbicides. Our team developed an intravaginal ring (IVR) that delivers tenofovir (TFV) (8-10 mg/day) alone...
8.
Thurman A, Chandra N, Schwartz J, Brache V, Chen B, Asin S, et al.
AIDS Res Hum Retroviruses
. 2019 Apr;
35(9):853-864.
PMID: 30997816
Reproductive age women may choose to concurrently use topical antiretrovirals and hormonal contraceptives (HCs) to simultaneously prevent HIV-1 infection and unintended/mistimed pregnancy. There are conflicting data on the effect of...
9.
Marrazzo J, Rabe L, Kelly C, Richardson B, Deal C, Schwartz J, et al.
J Infect Dis
. 2019 Feb;
219(12):1940-1947.
PMID: 30753642
Background: Genital infection with herpes simplex virus type 2 (HSV-2) is common and increases risk of human immunodeficiency virus (HIV) transmission and acquisition. Pericoital use of tenofovir (TFV) gel provided...
10.
Delany-Moretlwe S, Lombard C, Baron D, Bekker L, Nkala B, Ahmed K, et al.
Lancet Infect Dis
. 2018 Dec;
18(11):1241-1250.
PMID: 30507409
Background: Young women in southern Africa have substantial risk of HIV acquisition. Female-controlled biomedical interventions are needed to mitigate this risk. We aimed to assess the safety and efficacy of...